Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 1684

Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea

Prof Hyun Cheol Chung speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from the KEYNOTE-028 and KEYNOTE-158 studies looking at Pembrolizumab as treatment for advanced small-cell lung cancer (SCLC) after two or more lines of prior therapy.

Prof Chung reports that in KEYNOTE-028 patients were PD-L1 positive and the response rate seen was around 30%.

He also reports that a response rate of 19% was seen in KEYNOTE-158 (patients who did not express PD-L1) but promisingly the survival rate was 19 months.

Read more about this research here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation